ABSTRACT
This study aimed to evaluate if efficacy and tolerability of switching to vortioxetine is independent of previous SSRI or SNRI treatment in patients who had been inadequately treated for their current major depressive episode. Patients from a double-blind, 12-week comparator study were randomized (1:1) to vortioxetine (10-20â¯mg/day) or agomelatine (25-50â¯mg/day). The pre-defined primary efficacy endpoint was change from baseline to week 8 in MADRS total score analyzed by MMRM. An ANCOVA-LOCF was conducted as a sensitivity analysis. These analyses were repeated in subgroups according to previous antidepressant treatment. In the overall population, vortioxetine (nâ¯=â¯252) was significantly superior to agomelatine (nâ¯=â¯241) by -2.2 MADRS points (pâ¯<â¯0.01) at week 8. â¼77% (nâ¯=â¯189/vortioxetine, nâ¯=â¯188/agomelatine) were previously treated with an SSRI (citalopram, escitalopram, paroxetine, sertraline) and â¼23% (nâ¯=â¯62/vortioxetine, nâ¯=â¯52/agomelatine) with an SNRI (duloxetine, venlafaxine). Baseline characteristics were similar in all subgroups. Treatment differences (MMRM) in MADRS total score were -2.6 and -2.3 (nâ¯=â¯164/vortioxetine, nâ¯=â¯150/agomelatine) (pâ¯<â¯0.01) for patients switching from an SSRI and -1.8 and -1.5 (nâ¯=â¯56/vortioxetine, nâ¯=â¯40/agomelatine) (pâ¯>â¯0.05) from an SNRI at weeks 8 and 12, respectively; non-significant improvements were seen for each of the 6 previous antidepressants. Improvements in HAM-A, CGI-I, and EQ-5D scales were significant for the SSRI subgroup and non-significant for the SNRI subgroup. Withdrawal and adverse event rates were similar, regardless of previous SSRI or SNRI treatment. These subgroup analyses showed statistical superiority of vortioxetine to agomelatine in inadequate responders to SSRIs and statistically non-significant improvements in the smaller SNRI subgroup, while being equally well tolerated. TRIAL REGISTRATION: This study has the ClinicalTrials.gov identifier NCT01488071.
Subject(s)
Acetamides/pharmacology , Depressive Disorder, Major/drug therapy , Outcome Assessment, Health Care , Serotonin Agents/pharmacology , Vortioxetine/pharmacology , Acetamides/administration & dosage , Acetamides/adverse effects , Adolescent , Adult , Aged , Double-Blind Method , Drug Substitution , Female , Humans , Hypnotics and Sedatives , Male , Middle Aged , Receptors, Melatonin/agonists , Serotonin Agents/administration & dosage , Serotonin Agents/adverse effects , Selective Serotonin Reuptake Inhibitors/pharmacology , Serotonin and Noradrenaline Reuptake Inhibitors/pharmacology , Vortioxetine/administration & dosage , Vortioxetine/adverse effects , Young AdultABSTRACT
OBJECTIVE: This randomised, double-blind, 12-week study compared efficacy and tolerability of flexible-dose treatment with vortioxetine(10-20 mg/day) versus agomelatine (25-50 mg/day) in major depressive disorder patients with inadequate response to selective serotonin reuptake inhibitor (SSRI)/serotonin-noradrenaline reuptake inhibitor (SNRI) monotherapy. METHODS: Patients were switched directly from SSRI/SNRI to vortioxetine or agomelatine. Primary endpoint was change from baseline to week 8 in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score analysed by mixed model for repeated measurements, using a noninferiority test followed by a superiority test. Secondary endpoints included response and remission rates, anxiety symptoms(Hamilton Anxiety Rating Scale), Clinical Global Impression, overall functioning (Sheehan Disability Scale), health-related quality of life(EuroQol 5 Dimensions), productivity (work limitation questionnaire) and family functioning (Depression and Family Functioning Scale). RESULTS: Primary endpoint noninferiority was established and vortioxetine (n = 252) was superior to agomelatine (n = 241) by 2.2 MADRS points (p<0.01). Vortioxetine was also significantly superior in response and remission rates at weeks 8 and 12; MADRS, Hamilton Anxiety Rating Scale, Clinical Global Impression, Sheehan Disability Scale and EuroQol 5 Dimensions scores at week 4 onwards; work limitation questionnaire at week 8 and Depression and Family Functioning Scale at weeks 8 and 12. Fewer patients withdrew because of adverse events with vortioxetine (5.9% vs 9.5%). Adverse events (incidence ≥5%) were nausea, headache, dizziness and somnolence. CONCLUSIONS: Vortioxetine was noninferior and significantly superior to agomelatine in major depressive disorder patients with previous inadequate response to a single course of SSRI/SNRI monotherapy. Vortioxetine was safe and well tolerated.